Moderna, Inc. (MRNA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
29/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinMRNA / S&P 37.85% / 15.20% |
LoseMRNA / S&P -27.62% / 15.00% |
LoseMRNA / S&P 6.11% / 50.40% |
| 2026-Q11/3 |
WinMRNA / S&P 72.26% / -4.33% |
LoseMRNA / S&P -29.97% / 11.30% |
LoseMRNA / S&P -6.64% / 27.70% |
| 2025-Q41/3 |
WinMRNA / S&P 14.17% / 2.65% |
LoseMRNA / S&P -39.93% / 9.00% |
LoseMRNA / S&P -21.66% / 13.40% |
| 2025-Q31/3 |
LoseMRNA / S&P -6.38% / 8.12% |
LoseMRNA / S&P -56.07% / 4.61% |
WinMRNA / S&P 38.90% / 13.45% |
| 2025-Q20/3 |
LoseMRNA / S&P -2.68% / 10.94% |
LoseMRNA / S&P -39.05% / 4.83% |
LoseMRNA / S&P -51.01% / 10.63% |
| 2025-Q10/3 |
LoseMRNA / S&P -31.82% / -4.27% |
LoseMRNA / S&P -38.35% / 4.98% |
LoseMRNA / S&P -44.25% / 10.57% |
| 2024-Q40/3 |
LoseMRNA / S&P -37.78% / 2.41% |
LoseMRNA / S&P -52.75% / 5.25% |
LoseMRNA / S&P -25.16% / 6.15% |
| 2024-Q30/3 |
LoseMRNA / S&P -43.72% / 5.89% |
LoseMRNA / S&P -44.29% / 5.89% |
LoseMRNA / S&P -37.53% / 6.11% |
| 2024-Q21/3 |
WinMRNA / S&P 11.44% / 4.28% |
LoseMRNA / S&P -52.60% / 5.38% |
LoseMRNA / S&P -656.88% / 5.12% |
| 2024-Q10/3 |
LoseMRNA / S&P 7.15% / 10.56% |
LoseMRNA / S&P -65.78% / 5.71% |
LoseMRNA / S&P -234.77% / 5.59% |
| 2023-Q40/3 |
LoseMRNA / S&P -3.72% / 11.69% |
LoseMRNA / S&P -64.45% / 6.81% |
LoseMRNA / S&P -161.97% / 7.78% |
| 2023-Q30/3 |
LoseMRNA / S&P -14.99% / -3.27% |
LoseMRNA / S&P -57.36% / 7.52% |
LoseMRNA / S&P -133.65% / -5.03% |
| 2023-Q20/3 |
LoseMRNA / S&P -20.89% / 8.74% |
LoseMRNA / S&P -53.67% / 9.50% |
LoseMRNA / S&P -91.59% / -8.57% |
| 2023-Q10/3 |
LoseMRNA / S&P -14.50% / 7.50% |
LoseMRNA / S&P -33.37% / 10.77% |
LoseMRNA / S&P -65.85% / -15.69% |
| 2022-Q41/3 |
WinMRNA / S&P 51.90% / 7.56% |
LoseMRNA / S&P 4.29% / 11.88% |
LoseMRNA / S&P -29.27% / -17.99% |
| 2022-Q32/3 |
LoseMRNA / S&P -17.22% / -4.88% |
WinMRNA / S&P 80.80% / 13.47% |
WinMRNA / S&P 69.57% / -1.41% |
| 2022-Q22/3 |
LoseMRNA / S&P -17.07% / -16.10% |
WinMRNA / S&P 227.61% / 13.71% |
WinMRNA / S&P 309.61% / 11.04% |
| 2022-Q12/3 |
LoseMRNA / S&P -32.18% / -4.60% |
WinMRNA / S&P 727.23% / 15.97% |
WinMRNA / S&P 2644.35% / 42.23% |
| 2021-Q41/3 |
LoseMRNA / S&P -34.01% / 11.03% |
WinMRNA / S&P 2200.25% / 15.00% |
LoseMRNA / S&P -1550.77% / 96.40% |
| 2021-Q32/3 |
WinMRNA / S&P 63.78% / 0.58% |
WinMRNA / S&P 4708.27% / 10.77% |
LoseMRNA / S&P MRNA unavailable / 69.42% |
| 2021-Q22/3 |
WinMRNA / S&P 79.44% / 8.55% |
WinMRNA / S&P 6515.39% / 6.58% |
LoseMRNA / S&P MRNA unavailable / 51.81% |
| 2021-Q12/3 |
WinMRNA / S&P 25.35% / 6.17% |
WinMRNA / S&P 5135.32% / -1.06% |
LoseMRNA / S&P MRNA unavailable / 7.39% |
| 2020-Q42/3 |
WinMRNA / S&P 47.66% / 12.15% |
WinMRNA / S&P 1233.69% / -3.72% |
LoseMRNA / S&P MRNA unavailable / -33.42% |
| 2020-Q32/3 |
WinMRNA / S&P 10.19% / 8.93% |
WinMRNA / S&P 201.63% / -2.04% |
LoseMRNA / S&P MRNA unavailable / -27.10% |
| 2020-Q22/3 |
WinMRNA / S&P 114.39% / 20.54% |
WinMRNA / S&P -0.17% / -0.46% |
LoseMRNA / S&P MRNA unavailable / -27.11% |
| 2020-Q11/3 |
WinMRNA / S&P 53.12% / -19.60% |
LoseMRNA / S&P -57.25% / 3.47% |
LoseMRNA / S&P MRNA unavailable / -14.75% |
| 2019-Q41/3 |
WinMRNA / S&P 22.86% / 9.07% |
LoseMRNA / S&P -55.42% / 5.36% |
LoseMRNA / S&P MRNA unavailable / 2.99% |
| 2019-Q31/3 |
WinMRNA / S&P 8.74% / 1.70% |
LoseMRNA / S&P MRNA unavailable / 5.02% |
LoseMRNA / S&P MRNA unavailable / 0.21% |
| 2019-Q20/3 |
LoseMRNA / S&P -28.06% / 4.30% |
LoseMRNA / S&P MRNA unavailable / 6.64% |
LoseMRNA / S&P MRNA unavailable / 8.65% |
| 2019-Q11/3 |
WinMRNA / S&P 33.27% / 13.65% |
LoseMRNA / S&P MRNA unavailable / 8.12% |
LoseMRNA / S&P MRNA unavailable / 14.29% |
| 2018-Q40/3 |
LoseMRNA / S&P MRNA unavailable / -13.52% |
LoseMRNA / S&P MRNA unavailable / 9.05% |
LoseMRNA / S&P MRNA unavailable / 18.23% |
| 2018-Q30/3 |
LoseMRNA / S&P MRNA unavailable / 7.71% |
LoseMRNA / S&P MRNA unavailable / 10.21% |
LoseMRNA / S&P MRNA unavailable / 19.06% |
| 2018-Q20/3 |
LoseMRNA / S&P MRNA unavailable / 3.43% |
LoseMRNA / S&P MRNA unavailable / 9.03% |
LoseMRNA / S&P MRNA unavailable / 14.46% |
| 2018-Q10/3 |
LoseMRNA / S&P MRNA unavailable / -0.76% |
LoseMRNA / S&P MRNA unavailable / 7.68% |
LoseMRNA / S&P MRNA unavailable / 12.46% |
| 2017-Q40/3 |
LoseMRNA / S&P MRNA unavailable / 6.64% |
LoseMRNA / S&P MRNA unavailable / 7.03% |
LoseMRNA / S&P MRNA unavailable / 13.82% |
| 2017-Q30/3 |
LoseMRNA / S&P MRNA unavailable / 4.48% |
LoseMRNA / S&P MRNA unavailable / 5.68% |
LoseMRNA / S&P MRNA unavailable / 17.57% |
| 2017-Q20/3 |
LoseMRNA / S&P MRNA unavailable / 3.09% |
LoseMRNA / S&P MRNA unavailable / 4.83% |
LoseMRNA / S&P MRNA unavailable / 17.74% |
| 2017-Q10/3 |
LoseMRNA / S&P MRNA unavailable / 6.07% |
LoseMRNA / S&P MRNA unavailable / 3.67% |
LoseMRNA / S&P MRNA unavailable / 13.32% |
| 2016-Q40/3 |
LoseMRNA / S&P MRNA unavailable / 3.82% |
LoseMRNA / S&P MRNA unavailable / 2.09% |
LoseMRNA / S&P MRNA unavailable / 7.05% |
| 2016-Q30/3 |
LoseMRNA / S&P MRNA unavailable / 3.85% |
LoseMRNA / S&P MRNA unavailable / 0.20% |
LoseMRNA / S&P MRNA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | MRNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 492.65% | 20.78% |
| Annualized return | 492.65% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | MRNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -63.39% | 83.14% |
| Annualized return | -18.20% | 12.86% |
10Y · 2018-12-07 to 2026-08-27
| Metric | MRNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 667.58% | 319.30% |
| Annualized return | 22.61% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |